RxDoctor Payments Data

Richard Visci, DO

Obstetrics & Gynecology · Sandusky, OHNPI 1386667194

Payments from drug & device makers

$5,368in general payments, 2019–2025

Across 260 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$810
  • AbbVie$673
  • Organon$396
  • Amgen$356
  • Applied Medical Resources Corporation$248
  • Sumitomo Pharma America, Inc.$230
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$1573%
  • Food & beverage$4,73788%
  • Education$4749%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,368 in reported general payments places this provider in the 90th percentile of 1,376 obstetrics & gynecology providers in Ohio.

See all obstetrics & gynecology providers in Ohio

Medicare billing

Part B allowed, 2024
$77,387
Medicare patients
227
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron71$62,168
Estradiol203$13,464
ValacyclovirValacyclovir Hcl39$1,971
Trospium Chloride14$1,086
Ibandronate Sodium16$649
Oxybutynin Chloride ErOxybutynin Chloride35$431
Medroxyprogesterone Acetate18$408
Metronidazole20$357
Clobetasol Propionate13$356
Alendronate Sodium29$262
Nystatin18$226
Fluconazole29$208
Triamcinolone Acetonide37$120
Ibuprofen16$74
Venlafaxine Hcl ErVenlafaxine Hcl13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$810$62,16871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,376 obstetrics & gynecology providers in Ohio.

Other obstetrics & gynecology in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →